Summit Hotel Properties, Inc. (INN-PF)
- CNW Group
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), is pleased to announce that is has reached a key milestone: the Company submitted its letter of application for a Pre-IND meeting, the first phase in the FDA approval process in the United States for Innocan's Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain.
- CNW Group
Innocan Pharma Reports Full Year 2023 Results with Revenues up Nearly 6X to $13.7M
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies is pleased to announce its audited financial consolidated results for the year ended December 31, 2023.
- PR Newswire
SUMMIT HOTEL PROPERTIES ANNOUNCES FIRST QUARTER 2024 EARNINGS RELEASE DATE
Summit Hotel Properties, Inc. (NYSE: INN) (the "Company") today announced that it will report financial results for the first quarter of 2024 on Wednesday, May 1, 2024, after the market closes.
